Verification evidence is still being completed.
PDF / print export
Inpharmatis
Riga, Latvia
- Verified lead
- Polina Dombure
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Founder and Chief Executive Officer
- 2026 technical specialization
- Regulatory Affairs, Pharmacovigilance, GMP and GDP Compliance, and eCTD Publishing
- Review cycle
- 24 April 2026
- Full address
- Raina bulvaris 11, 3rd floor, Riga, LV-1050, Latvia
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Pharma Tech Outlook feature naming Polina Dombure as CEO of Inpharmatis Group.
- Editorial note
- Riga regulatory consultancy with a named founder-CEO, multi-country pharmacovigilance and GMP auditing coverage across EU plus CIS, and a proprietary Prudenta eSolutions stack.
Regulatory Affairs, Pharmacovigilance, GMP and GDP Compliance, and eCTD Publishing
Pharma Tech Outlook recognition as Top Compliance Service Company Europe 2021, Public leadership disclosure on LinkedIn, Documented multi-country regulatory service scope
Riga regulatory consultancy with a named founder-CEO, multi-country pharmacovigilance and GMP auditing coverage across EU plus CIS, and a proprietary Prudenta eSolutions stack.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Riga regulatory consultancy with a named founder-CEO, multi-country pharmacovigilance and GMP auditing coverage across EU plus CIS, and a proprietary Prudenta eSolutions stack.
Contact & location
- Website
- inpharmatis.com
- Lead
- Polina Dombure (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Regulatory consulting service delivery across EU and CIS
- Capabilities
- Regulatory Affairs in EU and CIS · Pharmacovigilance System Operation and QPPV · GMP and GDP Compliance Auditing
- Founded
- 2009
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED APRIL 2026
Polina Dombure
Founder and Chief Executive Officer
Full addressRaina bulvaris 11, 3rd floor, Riga, LV-1050, Latvia
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Inpharmatis contacts page listing Raina bulvaris 11 in Riga as the head office address.
Open sourceRegulatory consulting service delivery across EU and CIS
Riga, Latvia. Regulatory Affairs, Pharmacovigilance, GMP and GDP Compliance, and eCTD Publishing. Review completed on 24 Apr 2026.
Multi-jurisdictional regulatory advisory across EU and CIS
Pharma Tech Outlook recognition as Top Compliance Service Company Europe 2021, Public leadership disclosure on LinkedIn, Documented multi-country regulatory service scope
Regulatory Affairs, Pharmacovigilance, GMP and GDP Compliance, and eCTD Publishing
Riga regulatory consultancy with a named founder-CEO, multi-country pharmacovigilance and GMP auditing coverage across EU plus CIS, and a proprietary Prudenta eSolutions stack.
Editorial note
Inpharmatis offers a rare full-scope pharmacovigilance and regulatory consulting surface that bridges EU quality standards and CIS market access, anchored by a named founder-CEO and a proprietary eCTD and literature-monitoring toolset.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Regulatory Affairs in EU and CIS
Pharmacovigilance System Operation and QPPV
GMP and GDP Compliance Auditing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
eCTD publishing systems
Prudenta local-literature monitoring platform
Multi-country regulatory intelligence
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Inpharmatis located?
- Inpharmatis operates from Raina bulvaris 11, 3rd floor, Riga, LV-1050, Latvia, Riga, Latvia.
- Who runs Inpharmatis?
- Inpharmatis is led by Polina Dombure, Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What does Inpharmatis do?
- Riga regulatory consultancy with a named founder-CEO, multi-country pharmacovigilance and GMP auditing coverage across EU plus CIS, and a proprietary Prudenta eSolutions stack. Core capabilities: Regulatory Affairs in EU and CIS, Pharmacovigilance System Operation and QPPV, GMP and GDP Compliance Auditing.
Editorial context
Related technical briefs
Briefs that name Riga as a covered market or city.